Zhitong Finance App News, Corning Jerry Pharmaceutical-B (09966.HK) issued an announcement. The US Food and Drug Administration (FDA) has approved JSKN021 (a bispecific antibody double load coupling drug (ADC (s))) independently developed by the company and targeting epidermal growth factor receptor (EGFR) /human epidermal growth factor receptor 3 (HER3)) to conduct phase I clinical research (study number: JSKN021-101), a new drug clinical trial application (IND) for overseas clinical development of JSKN021 Officially launched.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.